New combo therapy aims to shrink hard-to-treat thymic tumors before surgery
NCT ID NCT07479628
First seen Mar 20, 2026 · Last updated May 21, 2026 · Updated 10 times
Summary
This study tests whether giving a combination of the immunotherapy drug adebrelimab, chemotherapy, and radiation before surgery can shrink tumors in people with locally advanced thymic carcinoma. About 31 participants will receive 2-4 cycles of this neoadjuvant therapy, then surgery if the tumor becomes removable, followed by up to a year of maintenance adebrelimab. The goal is to see how many patients have a significant tumor response and whether the treatment is safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYMIC CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.